MBX Biosciences, Inc. $MBX Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in MBX Biosciences, Inc. (NASDAQ:MBX) by 1,197.9% in the first quarter, Holdings Channel reports. The firm owned 22,765 shares of the company’s stock after purchasing an additional 21,011 shares during the period. California State Teachers Retirement System’s holdings in MBX Biosciences were worth $680,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Wellington Management Group LLP increased its stake in MBX Biosciences by 112.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,823,336 shares of the company’s stock valued at $84,408,000 after purchasing an additional 2,556,708 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in shares of MBX Biosciences by 1,568.8% during the first quarter. Aaron Wealth Advisors LLC now owns 1,168,176 shares of the company’s stock valued at $34,870,000 after buying an additional 1,098,176 shares during the last quarter. Braidwell LP acquired a new position in shares of MBX Biosciences in the 4th quarter valued at $32,127,000. Deep Track Capital LP increased its position in shares of MBX Biosciences by 43.9% in the 3rd quarter. Deep Track Capital LP now owns 3,150,000 shares of the company’s stock valued at $55,125,000 after acquiring an additional 961,408 shares during the period. Finally, Eventide Asset Management LLC purchased a new position in MBX Biosciences in the 4th quarter worth $28,071,000.

MBX Biosciences Price Performance

Shares of NASDAQ MBX opened at $68.57 on Friday. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -28.45 and a beta of 0.10. The firm’s 50 day simple moving average is $55.85 and its 200-day simple moving average is $40.94. MBX Biosciences, Inc. has a 12 month low of $9.63 and a 12 month high of $72.64.

MBX Biosciences (NASDAQ:MBX) last posted its earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.10). Analysts anticipate that MBX Biosciences, Inc. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research report on Friday, July 17th. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of MBX Biosciences in a research note on Thursday, July 23rd. Wall Street Zen downgraded MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Truist Financial upped their target price on MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a research report on Monday. Finally, Mizuho raised their price target on shares of MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, MBX Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.62.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.